Company intelligence / Profile preview
Chiesi Farmaceutici S.p.A.
Parma, Emilia-Romagna, Italychiesi.com ↗
- Ownership
- Private
- Employees
- ~6500
- Development stage
- Other
01
Overview
Chiesi has a diverse portfolio of marketed products across respiratory, neonatology, and rare disease areas. They have achieved European marketing authorization for velmanase alfa for alfa-mannosidosis and have stem cell treatments for limbal stem cell deficiency.
- Therapeutic areas
- PulmonologyRare DiseasesCardiovascular
- Modalities
- Small moleculesbiotechnology products (proteins)advanced therapeutics (gene and cell therapy)enzyme replacement therapy
- Industry
- Pharma
02
Drug pipeline
66 assets65 more assets in the full pipeline.
03
Partnerships
Kamada (inhaled alpha 1 antitrypsin)uniQure (gene therapy)Holostem (tissue-regeneration)Veloxis (immunosuppressant tacrolimus)Zymenex (acquisition)
Beyond the preview
Go deeper on Chiesi Farmaceutici S.p.A..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chiesi Farmaceutici S.p.A..